SAN
JOSE, Calif., Oct. 10,
2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ:
ANIX), a biotechnology company focused on the treatment and
prevention of cancer and infectious diseases, today
announced a presentation outlining its ovarian cancer CAR-T
therapy trial at the Society for Immunotherapy of Cancer (SITC)
37th Annual Meeting being held November 8-12, 2022. The presentation,
titled "Phase I clinical trial of autologous T-cells genetically
engineered with a chimeric receptor to target the
follicle-stimulating hormone receptor (FSHR) in patients with
recurrent ovarian cancer (OVCA)," will be presented by the study's
principal investigator, Dr. Robert
Wenham, Chair of the Gynecologic Oncology Department at
Moffitt Cancer Center, Anixa's collaboration partner.
Additional presentation details can be found
below:
Abstract #: 672
Date/Time: November 10,
2022, 9:00 AM EST
About Anixa Biosciences,
Inc.
Anixa is a clinical-stage biotechnology company with programs
addressing cancer and infectious disease. Anixa's portfolio
of therapeutics includes a cancer immunotherapy program being
developed in collaboration with Moffitt Cancer Center, which uses a
novel type of CAR-T, known as chimeric endocrine receptor T-cell
(CER-T) technology, and, with partner MolGenie GmbH, a COVID-19
program focused on compounds targeting the Mpro enzyme
of SARS-CoV-2, which is largely conserved across all recently
identified variants. The company's vaccine portfolio includes
a novel vaccine being developed in collaboration with Cleveland
Clinic to prevent breast cancer – specifically triple negative
breast cancer (TNBC), the most lethal form of the disease – as well
as a vaccine to prevent ovarian cancer. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of cancer.
Anixa's unique business model of partnering with world-renowned
research institutions on clinical development allows the company to
continually examine emerging technologies in complementary fields
for further development and commercialization. To learn more,
visit www.anixa.com or follow Anixa on Twitter, LinkedIn and
Facebook.
Forward-Looking Statements: Statements that
are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form
8-K. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law. You are cautioned not to unduly rely on such
forward-looking statements when evaluating the information
presented in this press release.
Contact:
Mike
Catelani
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-presentation-on-ovarian-cancer-car-t-therapy-trial-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-301644253.html
SOURCE Anixa Biosciences, Inc.